查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2032580

免疫療法藥物市場報告：按藥物類型、治療領域、最終用戶和地區分類（2026-2034 年）

Immunotherapy Drugs Market Report by Drug Type, Therapy Area, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3個工作天內

價格

2025年全球免疫療法市場規模達2,464億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到4,643億美元，2026年至2034年的複合年成長率（CAGR）為7.07%。市場成長的主要促進因素包括：人口老化導致各種癌症發病率上升、對個人化醫療的需求不斷成長以及公眾對早期檢測和治療意識的提高。

免疫療法藥物是一種旨在利用或調節免疫系統來對抗或控制疾病的醫療治療方法。它們針對特定的細胞或蛋白質，有助於最大限度地減少對健康組織的損傷。與其他治療方法相比，免疫療法藥物的抗藥性風險更低，治療效果更好，副作用更少。它們被用於治療多種癌症，包括黑色素瘤、肺癌和乳癌。此外，它們也用於控制某些過敏反應，以及治療類風濕性關節炎、紅斑性狼瘡和多發性硬化症等疾病。而且，免疫療法藥物在控制慢性發炎性疾病的有效性，也使得全球對這類藥物的需求日益成長。

全球製藥業的成長和藥局的擴張創造了良好的市場前景。此外，生技公司、製藥公司和研究機構之間的策略聯盟和併購正在推動免疫療法產品的研發和商業化進程。同時，人工智慧（AI）和巨量資料分析在研發活動中的應用提高了效率和準確性。這些技術的融合能夠實現快速標靶識別、最佳化臨床試驗以及預測患者反應。

免疫療法藥物市場的趨勢與促進因素：

目標疾病盛行率增加

生活方式的改變和不健康的飲食習慣導致癌症發病率上升，推動了對創新有效治療方法（例如免疫療法）的需求成長。此外，對早期檢測和個人化治療方案日益成長的需求也促使患者和醫療專業人員採用這些先進治療方法。同時，快速的都市化和有害汽車廢氣造成的污染日益嚴重，導致各種慢性疾病的發生，為免疫療法創造了新的機會。此外，老年人口的不斷成長，使得老年人更容易患腫瘤、癌症和其他健康問題，這也進一步刺激了對有效治療方法和技術（例如免疫療法藥物）的需求。

個人化醫療的普及

個人化醫療在各個醫療領域的日益普及，推動了以病人為中心的醫療模式，對市場產生了正面影響。此外，次世代定序和生物標記分析等先進診斷工具的開發，使得精準識別適合特定免疫療法的患者成為可能。這些診斷技術的進步有助於早期療育，並實現個人化治療方案，從而提升免疫療法的整體療效。同時，個人化免疫療法減少了試驗誤治療的可能性。此外，這種標靶治療方式最大限度地減少了無效治療方法的使用，避免了不必要的副作用，加快了康復速度，並降低了醫療成本，從而促進了市場成長。

來自政府和監管機構的支持

世界各國政府和監管機構持續關注免疫療法藥物和治療方法的研發，為市場創造了有利前景。此外，各國政府和監管機構也為開發新型免疫療法和最佳化現有療法所需的深入研究提供資金支持。同時，政府、研究機構和私人公司之間的夥伴關係也促進了市場成長。這些合作有助於知識交流，並加速突破性免疫療法的跨國研發。此外，各國政府推出的多項支持性醫療政策也提高了免疫療法的普及率和健保覆蓋率。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球免疫療法藥物市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依藥物類型分類

  • 單株抗體
  • 疫苗
  • α干擾素和BETA干擾素
  • 白細胞介素

第7章 市場區隔：依治療領域分類

  • 癌症
  • 自體免疫/發炎性疾病
  • 感染疾病
  • 其他

第8章 市場區隔：依最終用戶分類

  • 醫院
  • 診所
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • AstraZeneca plc
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche AG
    • GSK plc
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112026A6639

The global immunotherapy drugs market size reached USD 246.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 464.3 Billion by 2034, exhibiting a growth rate (CAGR) of 7.07% during 2026-2034. The growing prevalence of different cancer types due to the aging population, rising demand for personalized medicines, and the increasing awareness among individuals about early detection and treatment are some of the major factors propelling the market.

Immunotherapy drugs are medical treatments designed to utilize or modify the immune system to fight or control diseases. They focus on specific cells and proteins and aid in minimizing harm to healthy tissues. They reduce the likelihood of developing resistance, offer better outcomes, and have fewer side effects as compared to other treatments. They are utilized in treating various types of cancers, including melanoma, lung, and breast cancer. They are also used in managing specific allergic reactions and treating diseases like rheumatoid arthritis, lupus, and multiple sclerosis. Besides this, as they are effective in controlling chronic inflammatory diseases, the demand for immunotherapy drugs is increasing across the globe.

The rise in the pharmaceutical industry and the expansion of pharmacies worldwide is offering a favorable market outlook. Moreover, strategic collaborations and mergers and acquisitions (M&A) between biotech firms, pharmaceutical companies, and research institutions are supporting the research, development, and commercialization activities of immunotherapy products. Furthermore, the integration of artificial intelligence (AI) and big data analytics in research and development (R&D) activities is enhancing efficiency and precision. This technological integration is enabling the rapid identification of targets, optimization of clinical trials, and prediction of patient responses .

IMMUNOTHERAPY DRUGS MARKET TRENDS/DRIVERS:

The increasing prevalence of target diseases

The rising occurrence of different types of cancer due to lifestyle changes and unhealthy dietary patterns is catalyzing the demand for innovative and effective treatments like immunotherapy is growing. Additionally, the early detection and need for personalized therapy options are encouraging patients and healthcare providers to adopt these advanced treatment alternatives. Apart from this, rapid urbanization and rising pollution levels due to harmful vehicular emissions are resulting in various chronic diseases, which is creating new opportunities for immunotherapy treatments. Furthermore, the increasing aging population, which is highly susceptible to tumor, cancer, and other health conditions, is driving the need for effective treatments and technologies, like immunotherapy drugs.

Adoption of personalized medicines

The increasing utilization of personalized medicines in various medical fields to promote a more patient-centered approach is positively influencing the market. Additionally, the development of advanced diagnostic tools, such as next-generation sequencing and biomarker analysis, is enabling the precise identification of patients for specific immunotherapies. These advancements in diagnostics facilitate early intervention and allow for personalized treatment plans, which aid in enhancing the overall effectiveness of immunotherapy. Apart from this, personalized immunotherapies reduce the likelihood of trial-and-error approaches. Furthermore, this targeted approach minimizes the use of ineffective treatments, avoids unnecessary side effects, facilitates quicker recoveries, and reduces healthcare costs, which is contributing to market growth.

Governmental and regulatory support

Governments and regulatory bodies of various countries are continuously focusing on the development of immunotherapy drugs and therapies, which is offering a favorable market outlook. Additionally, they are providing financial support for conducting the in-depth studies required to develop novel immunotherapies and optimize existing ones. Apart from this, partnerships between governments, research institutions, and private companies are supporting market growth. These collaborations facilitate knowledge exchange and accelerate the development of groundbreaking immunotherapy treatments across borders. Furthermore, the introduction of several supportive governmental healthcare policies is encouraging the adoption and reimbursement of immunotherapies.

IMMUNOTHERAPY DRUGS INDUSTRY SEGMENTATION:

Breakup by Drug Type:

  • Monoclonal Antibodies
  • Vaccines
  • Interferons Alpha and Beta
  • Interleukins

Monoclonal antibodies represent the largest market segment

Breakup by Therapy Area:

  • Cancer
  • Autoimmune and Inflammatory Diseases
  • Infectious Diseases
  • Others

Cancer accounts for the majority of the market share

Breakup by End User:

  • Hospitals
  • Clinics
  • Others

Hospitals hold the majority of the market share

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest immunotherapy drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share as the region has a well-established healthcare infrastructure that allows for the efficient distribution and utilization of immunotherapy drugs. Sophisticated medical facilities and well-trained healthcare professionals facilitate the widespread adoption of these treatments. Additionally, the region witnesses substantial investments from public and private sectors in healthcare and biotechnology, which facilitates research, drug development, and commercialization of immunotherapy products. Apart from this, the regulatory bodies in North America, such as the Food and Drug Administration (FDA), offer a conducive environment for drug approval. Furthermore, strategic collaborations between academia, biotech firms, and pharmaceutical companies ensure a dynamic environment for continuous innovation and growth in the field of immunotherapy.

COMPETITIVE LANDSCAPE:

Companies are actively engaged in various activities to stay competitive and innovate. They are conducting extensive research and development (R&D) activities, working on discovering new targets and optimizing existing therapies. Additionally, these companies are forming strategic partnerships with academic institutions, leveraging their expertise to fuel innovation. Apart from this, they are investing in cutting-edge manufacturing technologies to produce immunotherapy drugs efficiently and at scale. Furthermore, regulatory teams within these companies are collaborating with governmental bodies to ensure compliance with emerging rules and gain expedited approvals for novel treatment. Moreover, many companies are actively participating in international conferences and symposia, sharing knowledge, and learning from global peers.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • GSK plc
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi S.A.

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Immunotherapy Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Monoclonal Antibodies
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Vaccines
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Interferons Alpha and Beta
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Interleukins
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Therapy Area

  • 7.1 Cancer
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Autoimmune and Inflammatory Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Infectious Diseases
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AstraZeneca plc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bayer AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Boehringer Ingelheim International GmbH
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Bristol-Myers Squibb Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 F. Hoffmann-La Roche AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 GSK plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Merck & Co. Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Sanofi S.A.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Immunotherapy Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Immunotherapy Drugs Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Immunotherapy Drugs Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Immunotherapy Drugs Market: Breakup by Type (in %), 2025
  • Figure 5: Global: Immunotherapy Drugs Market: Breakup by Therapy Area (in %), 2025
  • Figure 6: Global: Immunotherapy Drugs Market: Breakup by End User (in %), 2025
  • Figure 7: Global: Immunotherapy Drugs Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Immunotherapy Drugs (Monoclonal Antibodies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Immunotherapy Drugs (Monoclonal Antibodies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Immunotherapy Drugs (Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Immunotherapy Drugs (Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Immunotherapy Drugs (Interferons Alpha and Beta) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Immunotherapy Drugs (Interferons Alpha and Beta) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Immunotherapy Drugs (Interleukins) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Immunotherapy Drugs (Interleukins) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Immunotherapy Drugs (Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Immunotherapy Drugs (Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Immunotherapy Drugs (Autoimmune and Inflammatory Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Immunotherapy Drugs (Autoimmune and Inflammatory Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Immunotherapy Drugs (Infectious Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Immunotherapy Drugs (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Immunotherapy Drugs (Other Therapy Areas) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Immunotherapy Drugs (Other Therapy Areas) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Immunotherapy Drugs (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Immunotherapy Drugs (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Immunotherapy Drugs (Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Immunotherapy Drugs (Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Immunotherapy Drugs (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Immunotherapy Drugs (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: North America: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: North America: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: United States: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: United States: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Canada: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Canada: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Asia-Pacific: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Asia-Pacific: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: China: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: China: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Japan: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Japan: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: India: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: India: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: South Korea: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: South Korea: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Australia: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Australia: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Indonesia: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Indonesia: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Others: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Others: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Europe: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Europe: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Germany: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Germany: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: France: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: France: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: United Kingdom: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: United Kingdom: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Italy: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Italy: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Spain: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Spain: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Russia: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Russia: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Others: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Others: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Latin America: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Latin America: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Brazil: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Brazil: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Mexico: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Mexico: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Others: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Others: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Middle East and Africa: Immunotherapy Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Middle East and Africa: Immunotherapy Drugs Market: Breakup by Country (in %), 2025
  • Figure 78: Middle East and Africa: Immunotherapy Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Global: Immunotherapy Drugs Industry: SWOT Analysis
  • Figure 80: Global: Immunotherapy Drugs Industry: Value Chain Analysis
  • Figure 81: Global: Immunotherapy Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Immunotherapy Drugs Market: Key Industry Highlights, 2025 & 2034
  • Table 2: Global: Immunotherapy Drugs Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Immunotherapy Drugs Market Forecast: Breakup by Therapy Area (in Million USD), 2026-2034
  • Table 4: Global: Immunotherapy Drugs Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 5: Global: Immunotherapy Drugs Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Immunotherapy Drugs Market: Competitive Structure
  • Table 7: Global: Immunotherapy Drugs Market: Key Players